MDLinx E-mail Article

To email this article, enter your own "From Email" address, the recipient's "To Email" address, and click the "Send Email" button. You may send to up to 5 emails at a time.


* From Email: 
* To Email: 
To Email: 
To Email: 
To Email: 
To Email: 
Email Subject Line: 
Comments:

Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: A randomized, phase III study by the Danish breast cancer cooperative group

Nielsen DL et al. – GD compared with docetaxel demonstrated increased TTP in metastatic breast cancer. RR and OS were similar. The addition of gemcitabine failed to demonstrate any clinically meaningful benefit when combined with docetaxel.

Methods

  • Predominantly human epidermal growth factor receptor 2 (HER2) –negative patients were randomly assigned to gemcitabine (1,000 mg/m2) on days 1 and 8 plus docetaxel (75 mg/m2) on day 8 or to docetaxel (100 mg/m2) on day 1, every 21 days
  • Patients were untreated or had prior (neo)adjuvant chemotherapy or a single anthracycline-based chemotherapy regimen for metastatic breast cancer
  • Primary end point was time to progression (TTP), and secondary end points were OS, response rate (RR), and toxicity

Results
  • 170 patients were allocated to GD, and 167 were allocated to docetaxel
  • Median TTP on GD was 10.3 months versus 8.3 months on docetaxel (HR, 0.77; 95% CI, 0.59 to 1.01; log-rank P = .06)
  • Adjusted Cox proportional model for TTP showed significant difference favoring combination (HR, 0.68; 95% CI, 0.51 to 0.90; P = .007)
  • RR was similar (GD, 36%; docetaxel, 34%), and OS was not different (P = .57)
  • Grades 3 to 4 neutropenia was common (GD, 75%; docetaxel, 69%); infection was reported in 26% and 21% of patients in the GD and docetaxel groups, respectively
  • Grades 3 to 4 thrombocytopenia was more frequent with GD (GD, 16%; docetaxel, 0.6%), and peripheral neuropathy was higher with docetaxel (GD, 5%; docetaxel, 16%)
[more...]

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close